Voyager and Palantir Developing AI-Powered Solution for Space Domain Awareness Applications
tracking
DENVER, March 10, 2025 /PRNewswire/ -- Voyager Technologies (Voyager), a global leader in defense technology and space solutions, is expanding its partnership with Palantir Technologies (NASDAQ: PLTR) to develop AI-powered solutions for enhanced Space Domain Awareness, enabling the proactive mitigation of potential collisions and threats.
'Our partnership is driving resilience into national security space by providing decision-makers with critical information on operationally relevant timescales,' said Matt Magaña, President of Defense and National Security at Voyager. 'We're developing an integrated solution, harnessing the power of AI with Palantir's software stack and taking advantage of real-time radio frequency streams and imagery to perform space-based object detection, identification, classification and tracking.'
The open-architecture SDA system pulls data from existing on-orbit assets using Voyager's VPX signal processing electronics and chassis, signals intelligence software and mission services capabilities and Palantir's AI/Machine-Learning engines. The team aims to rapidly transition the SDA system from TRL4 to TRL8 as a hosted payload in 2026.
'We are deepening our partnership with Voyager to deliver the transformative capabilities required to maintain our national security,' said Robert Imig, Head of USG Research and Development at Palantir. 'We are further extending the reach of our AI solutions from ground to space, a critical frontier where demands are intensifying as the environment grows increasingly contested.'
Palantir's AI capabilities will enhance Voyager's defense and national security solutions, enabling in situ signals processing for optical communication systems and more.
To learn more about Voyager's next-generation defense technologies please visit: https://voyagertechnologies.com/defense-natsec/
About Voyager Technologies:
Voyager Technologies (Voyager) is a defense and space technology company committed to advancing and delivering transformative, mission-critical solutions. By tackling the most complex challenges, Voyager aims to unlock new frontiers for human progress, fortify national security, and protect critical assets from ground to space. For more information visit: voyagertechnologies.com
Cautionary Statement Concerning Forward-Looking Statements
This press release contains 'forward-looking statements.' All statements, other than statements of historical fact, including those with respect to Voyager Technologies Inc.'s (the 'Company's') mission statement and growth strategy, are 'forward-looking statements.' Although the Company's management believes that such forward-looking statements are reasonable, it cannot guarantee that such expectations are, or will be, correct. These forward-looking statements involve many risks and uncertainties, which could cause the Company's future results to differ materially from those anticipated. Potential risks and uncertainties include, among others, general economic conditions and conditions affecting the industries in which the Company operates; the uncertainty of regulatory requirements and approvals; and the ability to obtain necessary financing on acceptable terms or at all. Readers should not place any undue reliance on forward-looking statements since they involve these known and unknown uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to operations, results of operations, growth strategy and liquidity. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons that actual results could differ materially from those.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 minutes ago
- Yahoo
Alpha Modus Agrees to Preferred Stock Exchange to Eliminate ~$41 Million in Mezzanine Equity, Strengthening Balance Sheet, and Fully Aligning Insider Interests
CHARLOTTE, N.C., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Alpha Modus Holdings, Inc. (NASDAQ: AMOD) ('Alpha Modus' or the 'Company'), a leader in AI-powered retail engagement technologies, today announced that it has entered into an agreement for a transformative capital restructuring that will eliminate approximately $41 million in mezzanine equity, dramatically reduce the Company's stockholders' deficit, retire its last remaining preferred stock, and deliver a cleaner, shareholder-aligned capital structure designed for sustainable growth. This transaction marks the final step in removing all preferred equity from Alpha Modus' balance sheet and strengthening the Company's financial foundation. The sole remaining preferred stockholder, The Alessi 2023 Irrevocable Trust, will exchange approximately 4.3 million shares of Series C Preferred Stock for 40,111,940 shares of Class A common stock. Under the terms of the agreement, the common shares that will be issued will be subject to a transfer restriction through June 13, 2026 (except for permitted transfers to affiliates), ensuring long-term insider alignment with shareholders. 'This is a decisive move that will not only eliminate ~$41 million in mezzanine equity and reduce the Company's stockholders' deficit, but it also sends a strong signal of insider confidence in Alpha Modus' long-term strategy,' said William Alessi, Chief Executive Officer of Alpha Modus. 'By agreeing to this exchange, my family has agreed to forego the downside price protection my family trust previously had holding preferred stock. We have created a simpler, stronger, and more investor-friendly capital structure that positions us to fully capitalize on our technology portfolio and market opportunities.' Transaction Benefits Eliminates ~$41 million in mezzanine equity, reducing stockholders' deficit and improving financial strength and flexibility. Retires all remaining Series C Preferred Stock Aligns insider holdings with long-term common shareholder interests. Simplifies the Company's capital structure, enhancing transparency for current and prospective investors. For more information, visit: About Alpha Modus Holdings Modus Holdings Inc. (NASDAQ: AMOD) is redefining the retail experience through its patented AI technologies, intelligent kiosks, and targeted consumer engagement tools. By integrating innovation with infrastructure, Alpha Modus is unlocking new monetization pathways for retailers and fintech providers alike. For more information and to access Alpha Modus' press room, visit: Forward-Looking StatementsThis press release includes 'forward-looking statements' within the meaning of the 'safe harbor' provisions of the United States Private Securities Litigation Reform Act of 1995. Alpha Modus's actual results may differ from their expectations, estimates, and projections, and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as 'expect,' 'estimate,' 'project,' 'budget,' 'forecast,' 'anticipate,' 'intend,' 'plan,' 'may,' 'will,' 'could,' 'should,' 'believes,' 'predicts,' 'potential,' 'continue,' and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements, but are not the exclusive means of identifying these statements. These forward-looking statements include, without limitation, Alpha Modus's expectations with respect to future performance. Alpha Modus cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Alpha Modus does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based. Contact Information Investor RelationsAlpha Modus Holdings, ir@ Follow us on LinkedIn | Follow us on XError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
13 minutes ago
- Yahoo
LIXTE Biotechnology Holdings Provides Corporate Update
-Completes Two Financings, Raising $6.5 Million- -Regains Compliance for Continued Listing on Nasdaq- -Announces Management Changes; Adds Two New Board Members- -Re-Establishes Scientific Advisory Committee- -Reports on New Findings Published in Scientific Journal Nature that Validate LIXTE's Ongoing Clinical Trials with LB-100- -Launches New Pre-Clinical Study- PASADENA, Calif, Aug. 18, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. ('LIXTE' or the 'Company') (Nasdaq: LIXT and LIXTW), a clinical-stage pharmaceutical company developing a new class of cancer therapy to enhance chemotherapy and immunotherapy, today provided an update on its recent activities. 'This has been a transformative period for our company,' said Geordan Pursglove, who became LIXTE's new Chairman and Chief Executive Officer in June. 'Momentum has been energized on several fronts, including securing essential funding to support our ongoing clinical trials, and to pursue long-term growth opportunities to enhance shareholder value.' Added Bas van der Baan, President and Chief Scientific Officer, 'We are especially proud of the recent publication in a leading medical journal, Nature, further validating the promise of our proprietary compound, LB-100, to treat ovarian and colorectal cancer. The recent formation of our medical advisory committee marks yet another strategic step toward our mission of developing and delivering effective solutions to patients battling cancer.' LIXTE's clinical trials are underway for ovarian cancer at the M.D. Anderson Cancer Center and at Northwestern University, supported by GSK. The Company's colorectal trial, supported by F. Hoffmann-La Roche, is being conducted at the Netherlands Cancer Institute. Summary of Recent Corporate Activities: Completion of two financings: a private placement with accredited investors, raising aggregate gross proceeds to the Company of approximately $5 million, and a registered direct offering with accredited investors, raising aggregate gross proceeds to the Company of approximately $1.5 million. Proceeds will be used for general corporate purposes and working capital and allowed the Company to regain compliance for continued listing on the Nasdaq Capital Market. Management and Board changes: Geordan Pursglove was appointed Chairman and Chief Executive officer in June 2025, succeeding Bas van der Baan, who became President and Chief Scientific Officer. Jason Sawyer and Michael Holloway, MD, joined LIXTE's Board as independent directors in July 2025, succeeding Stephen Forman, MD, and Yun Yen, MD, who were appointed to serve as members of a newly established Scientific Advisory Committee. Other committee members include Bas van der Baan and Board member René Bernards, PhD. Validation of LB-100: The medical journal Nature has published findings that validate LIXTE's ongoing clinical trials with LB-100. A team led by principal investigator Amir Jazaeri, MD, professor of Gynecologic Oncology and Reproductive Medicine at The University of Texas MD Anderson Cancer Center, studied survival outcomes of patients treated with immune checkpoint blockade therapy. The study showed that patients having tumors with inactivating mutations in PPP2R1A - the major scaffold subunit of protein phosphatase 2A (PP2A) - had significantly better overall survival, compared with patients who did not have this mutation in their tumors. ( New Pre-Clinical trial: LIXTE has initiated a new pre-clinical study in collaboration with Netherlands Cancer Institute (NKI) to test whether 'initiated' cells that carry mutations found in cancer cells can be eliminated by treatment with LB-100. The study represents a new opportunity in cancer prevention. About LIXTE Biotechnology Holdings, Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical company focused on new targets for cancer drug development and developing and commercializing cancer therapies. LIXTE has demonstrated that its first-in-class lead clinical PP2A inhibitor, LB-100, is well-tolerated in cancer patients at doses associated with anti-cancer activity. Based on extensive published preclinical data (see LB-100 has the potential to significantly enhance chemotherapies and immunotherapies and improve outcomes for patients with cancer. LIXTE's lead compound, LB-100, is part of a pioneering effort in an entirely new field of cancer biology – activation lethality – that is advancing a new treatment paradigm. LIXTE's new approach is covered by a comprehensive patent portfolio. Proof-of-concept clinical trials are currently in progress for Ovarian Clear Cell Carcinoma, Metastatic Colon Cancer and Advanced Soft Tissue Sarcoma. Additional information about LIXTE can be found at Forward-Looking Statement DisclaimerThis announcement contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. For example, statements regarding the Company's financial position, business strategy and other plans and objectives for future operations, and assumptions and predictions about future activities, including the continuing development of proprietary compounds, the planning, funding, coordination and potential results of clinical trials, the patent and legal costs to protect and maintain the Company's intellectual property worldwide, and the Company's ability to maintain compliance with Nasdaq's continued listing requirements, are all forward-looking statements. These statements are generally accompanied by words such as "intend," anticipate," "believe," "estimate," "potential(ly)," "continue," "forecast," "predict," "plan," "may," "will," "could," "would," "should," "expect" or the negative of such terms or other comparable terminology. The Company believes that the assumptions and expectations reflected in such forward-looking statements are reasonable, based on information available to it on the date hereof, but the Company cannot provide assurances that these assumptions and expectations will prove to have been correct or that the Company will take any action that the Company may presently be planning. However, these forward-looking statements are inherently subject to known and unknown risks and uncertainties. Actual results or experience may differ materially from those expected or anticipated in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, regulatory policies, available cash resources, research results, competition from other similar businesses, and market and general economic factors. Readers are urged to read the risk factors set forth in the Company's filings with the United States Securities and Exchange Commission at The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. For more information about LIXTE, contact: info@ General Phone: (631) 830-7092; Investor Phone: (888) 289-5533or PondelWilkinson Inc. Investor Relations pwinvestor@ Pondel: (310) 279-5965; Laurie Berman: (310) 279-5962Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
14 minutes ago
- Business Wire
MediaCo's Trailblazer Brian Fisher Elevated to Chief Revenue Officer
NEW YORK--(BUSINESS WIRE)--MediaCo Holding Inc. (Nasdaq: MDIA) today announced the promotion of Brian Fisher to Chief Revenue Officer (CRO), effective immediately. In this role, Fisher will lead revenue-generating functions across the portfolio, including national and local sales for linear, audio, events, and digital. 'Brian has been at the center of our growth story,' said Albert Rodriguez, CEO of MediaCo. 'In recent quarters, we've achieved record revenue, strengthened key partnerships, and entered new markets. We expect continued digital revenue momentum in the upcoming quarter, building on record results from Q2. Brian's leadership positions us well as we pursue our next phase of expansion.' Fisher most recently served as Senior Vice President of Video Sales, where he spearheaded innovation and revenue growth across digital, linear, and advanced TV platforms. He helped power a 345% surge in digital revenue during the first half of 2025, with digital now accounting for 33% of total advertising income. Prior to joining MediaCo, he held senior leadership roles at Disney, Tribune, and McCann-Erickson, where he was known for developing and scaling cutting-edge advertising solutions. A graduate of the University of Arizona, Fisher is widely recognized for his expertise in multicultural marketing and his ability to guide teams through the rapidly changing media landscape. 'I'm honored to take on this role at such an exciting time for MediaCo,' said Brian Fisher. 'We have an incredible opportunity to build on our momentum, expand our offerings, and deliver even greater value to our partners and audiences. I'm looking forward to working with our talented team to shape the next chapter of growth.' About MediaCo MediaCo Holding Inc. (Nasdaq: MDIA) is a diverse-owned, multi-platform media company serving multicultural audiences across the U.S. Through its influential brands—including Hot 97, WBLS, EstrellaTV, Estrella News, Que Buena Los Angeles, and the Don Cheto Radio Network—MediaCo reaches over 20 million people monthly via television, radio, digital, and streaming platforms. Its content spans music, news, and entertainment across major local and national markets. Learn more at
